Poolbeg Pharma Starts Clinical Trial for Cytokine Release Syndrome Preventative Treatment

MT Newswires · 2d ago
04:45 AM EDT, 07/13/2026 (MT Newswires) -- Poolbeg Pharma (POLB.L) dosed the first patient for its Polb 001 Topical clinical study to evaluate its lead asset, Polb 001, for the preventative treatment of Cytokine Release Syndrome. The trial will involve patients with relapsed/refractory multiple myeloma who are dosed with Johnson & Johnson's (JNJ.F) bispecific antibody teclistamab, according to a Monday release. The clinical-stage biopharmaceutical company expects to publish interim data from the study in the late summer of 2026.